Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

145.43 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 145.43
Bid (Size) 140.40 (1)
Ask (Size) 146.50 (1)
Prev. Close 145.43
Today's Range 145.43 - 145.43
52wk Range 117.58 - 212.00
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Where Alnylam Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Upgrades 
Via Benzinga

Performance

YTD
-16.38%
-16.38%
1 Month
+15.60%
+15.60%
3 Month
-11.99%
-11.99%
6 Month
-14.49%
-14.49%
1 Year
-12.32%
-12.32%

More News

Read More
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease
Via Benzinga
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
Via Benzinga
Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate
Via Benzinga
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
Via Benzinga
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Biggest Price Target Changes For Monday
Via Benzinga
Expert Ratings for Alnylam Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET
Via Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.